Your browser doesn't support javascript.
loading
Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.
Nassar, Kelsey W; Hintzsche, Jennifer D; Bagby, Stacey M; Espinoza, Veronica; Langouët-Astrié, Christophe; Amato, Carol M; Chimed, Tugs-Saikhan; Fujita, Mayumi; Robinson, William; Tan, Aik Choon; Schweppe, Rebecca E.
Afiliación
  • Nassar KW; Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Hintzsche JD; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Bagby SM; Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Espinoza V; Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Langouët-Astrié C; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Amato CM; Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Chimed TS; Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Fujita M; Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Robinson W; Department of Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Tan AC; Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Schweppe RE; University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Mol Cancer Ther ; 20(10): 2049-2060, 2021 10.
Article en En | MEDLINE | ID: mdl-34376578
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogénicas B-raf / MAP Quinasa Quinasa 1 / Quinasa 4 Dependiente de la Ciclina / Quinasa 6 Dependiente de la Ciclina / Melanoma Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogénicas B-raf / MAP Quinasa Quinasa 1 / Quinasa 4 Dependiente de la Ciclina / Quinasa 6 Dependiente de la Ciclina / Melanoma Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2021 Tipo del documento: Article